|Bid||243.40 x 243000|
|Ask||243.50 x 260500|
|Day's range||242.30 - 244.10|
|52-week range||218.30 - 273.00|
|PE ratio (TTM)||20.90|
|Earnings date||27 Jul 2017|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
China has slashed the price of dozens of top drugs from multinationals such as Roche, GSK and AstraZeneca by as much as 70 per cent as a condition of adding them to a government health insurance scheme. ...
The threat to its biologic drugs is still hazy, and it has defenses.
Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off....